Discordance of Adverse Molecular Features between the 22-Gene Genomic Classifier Score, Histologic Grade, and NCCN Risk Groups: Analysis of Over 200,000 Patients
Year: 2025
Type: article
Study design: Observational Study
Authors: M.J. Zelefsky, H.M. Ryu, P.T. Tran, J. Proudfoot, Y. Hao, M. Alshalalfa, E. Davicioni, P. Febbo, N.B. Desai, J.C. Hu, A. Briganti, E.M. Schaeffer, A.E. Ross, A.Y. Jia, D.R. Wise, D.E. Spratt
Institutions: NYU Langone Health, Veracyte (United States), University of Maryland, Baltimore, The University of Texas Southwestern Medical Center, Weill Cornell Medical Center, Vita-Salute San Raffaele University, Northwestern University, University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, NYU Langone’s Laura and Isaac Perlmutter Cancer Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: bronze
Funders: Prostate Cancer Foundation, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Biogen, American Society of Clinical Oncology, RefleXion Medical, Boston Scientific Corporation, Regeneron Pharmaceuticals, Exelixis, National Comprehensive Cancer Network, Incyte, NRG Oncology, Veracyte, Bayer HealthCare, EMD Serono, National Cancer Institute, Janssen Pharmaceuticals
OpenAlex ID: W4414557583